Developer of cell therapies for chronic kidney disease. The company develops cell therapy products that are programmed in the body to restore damaged kidney tissues by engrafting into, repairing or replacing damaged tissues or organ.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 01-Mar-2016 | 00.000 | Completed | Startup | ||
1. Angel (individual) | 05-Aug-2015 | 00.000 | 00.000 | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Timothy Bertram Ph.D | Chief Executive Officer, Board Member and Managing Director | ||
Deepak Jain Ph.D | Chief Operating Officer |
Name | Representing | Role | Since |
---|---|---|---|
Kim Westmoreland | Self | Board Member | 000 0000 |
Timothy Bertram Ph.D | RegenMedTX | Chief Executive Officer, Board Member and Managing Director | 000 0000 |
William Hawkins III | Self | Chairman | 000 0000 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 | 06-Mar-2015 | 000000000000000000 | 000.00 | Biotechnology | |
Tengion | Secondary Transaction - Private | Biotechnology |